Browsing Tag
Crohn’s disease
11 posts
AbbVie’s SKYRIZI wins FDA approval for ulcerative colitis treatment
The U.S. Food and Drug Administration (FDA) has approved SKYRIZI (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor developed by AbbVie,…
AbbVie to acquire Landos Biopharma to bolster autoimmune disease treatments
AbbVie Inc. (NYSE: ABBV) and Landos Biopharma, Inc. (NASDAQ: LABP) have announced a landmark agreement, marking a strategic…
Eli Lilly’s mirikizumab triumphs in Phase 3 Crohn’s disease study
Eli Lilly and Company (NYSE: LLY), a pharmaceutical leader, unveiled that mirikizumab, its cutting-edge interleukin-23p19 antagonist, has demonstrated…
Merck to acquire biotech company Prometheus Biosciences for $10.8bn
Merck has agreed to acquire Prometheus Biosciences, a Nasdaq-listed clinical-stage biotechnology company, in an all-cash deal worth around…
Crohn’s disease diet plan | What foods should be avoided by Crohn’s patients
In this post let us know about Crohn’s disease diet plan. What foods should be taken and what…
Crohn’s disease diagnosis and treatment
How is Crohn’s disease diagnosed? Crohn’s disease cannot be identified by any single test. The physician will start…
What is Crohn’s disease – symptoms and causes
What is Crohn’s disease? How common is Crohn’s disease? Crohn’s disease is a form of inflammatory bowel disease…
AzurRx BioPharma acquires US biotech company First Wave Bio for $229m
AzurRx BioPharma has signed a stock and cash deal worth $229 million to acquire Florida-based clinical-stage biotech company…
Amgen submits BLA for Infliximab biosimilar ABP 710 to FDA
Amgen Inc. has officially submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA)…
Mylan launches Hulio, a biosimilar to Humira, across major European markets
Mylan has officially launched Hulio, its biosimilar to AbbVie’s Humira (adalimumab), across major European markets. This launch follows…